Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

NuvaHealth vs Revel RX

NuvaHealth
Graded #65

Lower grade

vs+3.0999999999999943
Revel RX
Graded #47

Higher grade

The verdict

Revel RX takes it — 77.3/100 to 74.2/100.

Revel RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Revel RX is a Michigan-based telehealth weight-loss platform offering compounded semaglutide at $89/month and compounded tirzepatide at $155/month — flat-rate at every dose tier.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueRevel RX +20
76
96
Dose & formulationNuvaHealth +16
88
72
Clinical oversightRevel RX +2
82
84
Labs & monitoringEven
53
53
FulfillmentRevel RX +7
74
81
Contract termsEven
55
55
NuvaHealth · left barRevel RX · right bar

The numbers

MetricNuvaHealthRevel RX
WeighScore74.2/10077.3/100
GradeCC+
Scorecard rank#65#47
Semaglutide$139/mo (first-month rate, compounded)$89/mo (all doses, compounded)
Tirzepatide$229/mo (first-month rate, compounded)$155/mo (all doses, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
NuvaHealth

Graded #65 · C

Strengths

  • LegitScript Certified seal displayed on the marketing site (the standard third-party telehealth/pharmacy accreditation)
  • Free and fast delivery + 24/7 patient support disclosed on the home page
  • Newark, DE address suggests a US-incorporated entity (vs offshore)
  • $139 first-month price for compounded semaglutide injection is among the cheapest in the US compounded telehealth market
  • $229 first-month price for compounded tirzepatide injection sits in the lower-median range

Where it loses points

  • Standard ongoing monthly price NOT publicly disclosed (gated behind checkout) — patients should ask for the maintenance-dose price before committing
  • Specific legal entity name + state of incorporation NOT publicly disclosed on the home page — material YMYL transparency gap
  • Pharmacy partners NOT publicly named — material YMYL transparency gap
  • Per-state availability NOT enumerated; verify your state ships before purchase
  • Lab work + coaching support NOT publicly disclosed
Revel RX

Graded #47 · C+

Strengths

  • Industry-low flat pricing: $89/mo for compounded semaglutide and $155/mo for tirzepatide at every dose
  • LegitScript verified and BBB accredited with an A+ rating — above-average trust signals for a compounded platform
  • Named pharmacy partners: Manifest Pharmacy and Red Rock Home Pharmacy (503A + 503B facilities)
  • Free overnight cold shipping included; no hidden fees or dose-based price increases
  • Clinical review by MD Integrations, an independent medical group, before any prescription is issued

Where it loses points

  • States served are not publicly listed; eligible states requires completing intake to confirm coverage
  • No labs, coaching, or ongoing health support disclosed in any public materials
  • Compounded medications are not FDA-approved (site discloses this)
  • Newer brand with limited public patient reviews or Trustpilot rating
  • Pharmacy partners named but no accreditation details (PCAB, 503B cGMP) published on the site

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard